



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Hypoxanthine-¹³C₅,¹⁵N₄

| | |
|---------------------------|--|
| Cat. No.: | HY-N0091S |
| CAS No.: | 1987883-25-9 |
| Molecular Formula: | ¹³ C ₅ H ₄ ¹⁵ N ₄ O |
| Molecular Weight: | 145.05 |
| Target: | Endogenous Metabolite; Isotope-Labeled Compounds |
| Pathway: | Metabolic Enzyme/Protease; Others |
| Storage: | 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (68.94 mM; Need ultrasonic and warming)

| Concentration | Mass | | | |
|---------------|-----------|------------|------------|--|
| | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8942 mL | 34.4709 mL | 68.9417 mL | |
| 5 mM | 1.3788 mL | 6.8942 mL | 13.7883 mL | |
| 10 mM | 0.6894 mL | 3.4471 mL | 6.8942 mL | |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Hypoxanthine-¹³C₅,¹⁵N₄ is a ¹⁵N-labeled and ¹³C-labeled Dansyl chloride.

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[75].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-245.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-245.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA